$3.23
5.28% today
Nasdaq, Apr 03, 06:45 pm CET
ISIN
US92915B1061
Symbol
VYGR
Sector
Industry

Voyager Therapeutics, Inc. Stock price

$3.41
-0.50 12.79% 1M
-2.41 41.41% 6M
-2.26 39.86% YTD
-6.50 65.59% 1Y
-5.25 60.62% 3Y
-5.29 60.80% 5Y
-14.34 80.79% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.04 1.19%
ISIN
US92915B1061
Symbol
VYGR
Sector
Industry

Key metrics

Market capitalization $188.26m
Enterprise Value $-34.69m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.84
EV/Sales (TTM) EV/Sales -0.43
P/S ratio (TTM) P/S ratio 2.35
P/B ratio (TTM) P/B ratio 0.62
Revenue growth (TTM) Revenue growth -68.00%
Revenue (TTM) Revenue $80.00m
EBIT (operating result TTM) EBIT $-83.29m
Free Cash Flow (TTM) Free Cash Flow $-18.83m
Cash position $266.68m
EPS (TTM) EPS $-1.13
P/E forward negative
P/S forward 2.85
EV/Sales forward negative
Short interest 6.07%
Show more

Is Voyager Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Voyager Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Voyager Therapeutics, Inc. forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Voyager Therapeutics, Inc. forecast:

Buy
100%

Financial data from Voyager Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
80 80
68% 68%
100%
- Direct Costs 4.73 4.73
7% 7%
6%
75 75
69% 69%
94%
- Selling and Administrative Expenses 31 31
1% 1%
39%
- Research and Development Expense 123 123
40% 40%
153%
-79 -79
162% 162%
-98%
- Depreciation and Amortization 4.73 4.73
7% 7%
6%
EBIT (Operating Income) EBIT -83 -83
168% 168%
-104%
Net Profit -65 -65
149% 149%
-81%

In millions USD.

Don't miss a Thing! We will send you all news about Voyager Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Voyager Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 d...
Neutral
Seeking Alpha
23 days ago
Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer and Chief of Staff to the CEO Alfred Sandrock - President and Chief Executive Officer Toby Ferguson - Chief Medical Officer Todd Carter - Chief Scientific Officer Nathan Jorgensen - Chief Financial Officer Conference Call Par...
Neutral
GlobeNewsWire
23 days ago
- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 -
More Voyager Therapeutics, Inc. News

Company Profile

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Alfred Sandrock
Employees 172
Founded 2013
Website www.voyagertherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today